4 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Inspire Medical Systems, Inc., INSP
Summary: Inspire Medical Systems Inc. is a medical technology company. It focused on the development and commercialization of solutions for obstructive sleep apnea. The company's proprietary Inspire therapy is a neurostimulation technology which provides treatment for moderate to severe obstructive sleep apnea. Inspire Medical Systems Inc.is based in Minnesota, United States.
- Last Price: $229.22
- Price Change: $-11.93, -4.95%
- Yearly Gain: -16.63%
- Market Cap: $6.94B
- P/E Ratio: -318.36
Here are 3rd party ratings for INSP:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Bottom 41% (148 out of 250)
What is the sentiment on the street regarding Inspire Medical Systems, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Buy
- Insider Signal: Balanced
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in INSP or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INSP before you decide to make any investment.
Click here for chart >>
Ligand Pharmaceuticals Incorporated, LGND
Summary: Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
- Last Price: $72.47
- Price Change: $-0.05, -0.07%
- Yearly Gain: -5.93%
- Market Cap: $1.28B
- P/E Ratio: 23.92
Here are 3rd party ratings for LGND:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Strong Buy, Top 34% (86 out of 250)
What is the sentiment on the street regarding Ligand Pharmaceuticals Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in LGND or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on LGND before you decide to make any investment.
Click here for chart >>
Outlook Therapeutics, Inc., OTLK
Summary: Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
- Last Price: $8.17
- Price Change: $-0.12, -1.45%
- Yearly Gain: -65.09%
- Market Cap: $176.34M
- P/E Ratio: -2.04
Here are 3rd party ratings for OTLK:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 34% (86 out of 250)
What is the sentiment on the street regarding Outlook Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: High Risk
If you are interested in OTLK or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on OTLK before you decide to make any investment.
Click here for chart >>
Marinus Pharmaceuticals, Inc., MRNS
Summary: Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.
- Last Price: $1.38
- Price Change: $-0.03, -2.13%
- Yearly Gain: -82.96%
- Market Cap: $75.41M
- P/E Ratio: -0.52
Here are 3rd party ratings for MRNS:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 41% (147 out of 250)
What is the sentiment on the street regarding Marinus Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in MRNS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MRNS before you decide to make any investment.
Click here for chart >>
Thanks for reading!